the detection pipeline
CJC-1295 Detection and Anti-Doping Status
Seized sample, then mass spectrometry, then identification. The analytical pipeline that catches CJC-1295 in sport, and its WADA prohibited standing — drawn as a flowchart.
How CJC-1295 detection works
CJC-1295 detection began with a seized product and a mass spectrometer. Henninge and colleagues used high-resolution LC-MS/MS to identify CJC-1295 as the active ingredient in an unknown "GHRH" pharmaceutical preparation seized in an anti-doping context — a definitive structural identification of the peptide in a black-market product [2]. That is the root of the pipeline: an unknown preparation enters the laboratory, high-resolution tandem mass spectrometry resolves its sequence, and the compound is named.
From that root, the analytical toolkit branched. Qualitative identification of GHRH analogs in human plasma by immunoaffinity purification and LC-MS provided an earlier confirmatory approach [3]. An immuno-PCR screen was then developed to detect CJC-1295 and other GHRH analogs at low concentrations, sharpening surveillance for these peptides [4]. The arms race is documented in a dedicated review of advances in detecting GHRH synthetic analogs [5], and a confirmatory LC-MS/MS method was validated for CJC-1295 in equine plasma, reflecting that the prohibition reaches animal sport as well [13]. Each branch hangs off the same spine: separate the peptide, read it by mass spectrometry, confirm the identity. The WADA prohibited status is what makes a positive identification actionable.
How is CJC-1295 detected in anti-doping testing?
How is CJC-1295 detected in anti-doping testing?
Anti-doping laboratories identify CJC-1295 with high-resolution LC-MS/MS, first used to identify it in a seized GHRH preparation [2], and screens including immuno-PCR and immunoaffinity-LC-MS have been developed for GHRH analogs in human and equine matrices [3][4][13]. The combination of a sensitive screen and a confirmatory mass-spectrometry method is the standard structure: screen broadly, then confirm the exact sequence.
What is CJC-1295's WADA status for tested athletes?
The WADA Prohibited List bans growth-hormone-releasing factors and their analogs — CJC-1295 included — under Section S2 at all times, in and out of competition [14]. Section S2 covers Peptide Hormones, Growth Factors, Related Substances and Mimetics, and the "at all times" status means there is no permitted window for a tested athlete. Bodies such as the NCAA enforce parallel prohibitions, and the detection methods above make the ban enforceable rather than nominal.
Why detection is well-established here
CJC-1295 is an unusually well-characterized target for anti-doping science because its discovery in sport and its analytical identification happened together. The same 2010 LC-MS/MS work that confirmed its presence in a seized preparation also pinned down the mass and fragmentation signature laboratories now screen against [2]. Synthetic peptides of this size leave a distinct mass-spectrometric fingerprint, and the immuno-PCR and immunoaffinity approaches add sensitivity at low concentrations where the parent screen might miss a faint signal [3][4].
The equine method matters for the same reason the human methods do: a prohibited GHRH analog needs a validated confirmatory assay in every matrix where it might be abused, and CJC-1295 now has one in both human and equine plasma [13]. None of this is a deterrent claim — it is a description of the analytical record. The compound is detectable, the methods are published, and the prohibition under Section S2 is permanent [14].
Why the DAC half-life makes a hard detection target
The same albumin conjugation that gives CJC-1295 DAC its multi-day half-life also lengthens the window in which it can be found. Because the DAC form circulates for days — an estimated 5.8 to 8.1 days, with IGF-1 effects persisting up to 28 days after multiple doses [1] — a sample drawn well after administration can still carry the parent peptide or its signature. A short-acting compound clears the detectable window quickly; a long-acting one does not. That pharmacokinetic fact is what makes the analytical methods practically useful rather than merely possible.
The detection record also turns the DAC-versus-no-DAC distinction into more than a pharmacology footnote. The methods developed to identify CJC-1295 target the synthetic sequence and its mass, so they bear on both forms of the molecule; the durations differ, but the chemical identity a mass spectrometer reads is shared. For a tested athlete, the practical takeaway is that the prohibition under Section S2 covers the substance class and its analogs at all times [14] — and the laboratory tools to enforce it are published and validated. This page is a description of the analytical and regulatory record, not advice on testing, evasion, or use of any kind.